These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 24738883)

  • 21. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multicenter, Randomized, Controlled Study Comparing Tafluprost/Timolol Fixed Combination with Latanoprost/Timolol Fixed Combination in Primary Open-Angle Glaucoma and Ocular Hypertension.
    Suzuki K; Otsuka N; Hizaki H; Hashimoto M; Kuwayama Y;
    Adv Ther; 2018 Jun; 35(6):796-808. PubMed ID: 29873009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study.
    Uusitalo H; Pillunat LE; Ropo A;
    Acta Ophthalmol; 2010 Feb; 88(1):12-9. PubMed ID: 20420586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution.
    Barnebey HS; Orengo-Nania S; Flowers BE; Samples J; Mallick S; Landry TA; Bergamini MV
    Am J Ophthalmol; 2005 Jul; 140(1):1-7. PubMed ID: 15990081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study.
    Bourne RRA; Kaarniranta K; Lorenz K; Traverso CE; Vuorinen J; Ropo A
    BMJ Open; 2019 Apr; 9(4):e024129. PubMed ID: 30944129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of bimatoprost/timolol fixed combination in Chinese patients with open-angle glaucoma or ocular hypertension.
    Ling Z; Zhang M; Hu Y; Yin Z; Xing Y; Fang A; Ye J; Chen X; Liu D; Wang Y; Sun W; Dong Y; Sun X
    Chin Med J (Engl); 2014; 127(5):905-10. PubMed ID: 24571886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of country-level data from the VISIONARY study examining treatment outcomes with preservative-free tafluprost/timolol fixed-dose combination therapy.
    Holló G; Kirwan J; Lopez-Lopez F; Zimina M; Fassari C; Oddone F;
    Curr Med Res Opin; 2022 Jul; 38(7):1189-1201. PubMed ID: 35621005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension.
    Schuman JS; Katz GJ; Lewis RA; Henry JC; Mallick S; Wells DT; Sullivan EK; Landry TA; Bergamini MV; Robertson SM
    Am J Ophthalmol; 2005 Aug; 140(2):242-50. PubMed ID: 16086946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preservative-free tafluprost/timolol fixed combination: comparative 24-h efficacy administered morning or evening in open-angle glaucoma patients.
    Konstas AG; Katsanos A; Athanasopoulos GP; Voudouragkaki IC; Panagiotou ES; Pagkalidou E; Haidich AB; Giannoulis DA; Spathi E; Giannopoulos T; Katz LJ
    Expert Opin Pharmacother; 2018 Dec; 19(18):1981-1988. PubMed ID: 30328725
    [No Abstract]   [Full Text] [Related]  

  • 30. Tafluprost/Timolol: A Review in Open-Angle Glaucoma or Ocular Hypertension.
    Hoy SM
    Drugs; 2015 Oct; 75(15):1807-13. PubMed ID: 26431840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
    Sherwood MB; Craven ER; Chou C; DuBiner HB; Batoosingh AL; Schiffman RM; Whitcup SM
    Arch Ophthalmol; 2006 Sep; 124(9):1230-8. PubMed ID: 16966616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension.
    Olander K; Zimmerman TJ; Downes N; Schoenfelder J;
    Clin Ther; 2004 Oct; 26(10):1619-29. PubMed ID: 15598478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and tolerability of preservative-free eye drops containing a fixed combination of dorzolamide and timolol in glaucoma patients.
    Renieri G; Führer K; Scheithe K; Lorenz K; Pfeiffer N; Thieme H
    J Ocul Pharmacol Ther; 2010 Dec; 26(6):597-603. PubMed ID: 20977366
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
    Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
    J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
    Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
    Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of fixed-combination brinzolamide/timolol in Latin American patients with open-angle glaucoma or ocular hypertension previously on brimonidine/timolol fixed combination.
    Alezzandrini A; Hubatsch D; Alfaro R
    Adv Ther; 2014 Sep; 31(9):975-85. PubMed ID: 25138224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial.
    Fellman RL; Sullivan EK; Ratliff M; Silver LH; Whitson JT; Turner FD; Weiner AL; Davis AA;
    Ophthalmology; 2002 May; 109(5):998-1008. PubMed ID: 11986110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Preservative-free fixed combination in the treatment of open-angle glaucoma and ocular hypertension: the VISIONARY Study (EUPAS22204)].
    Karlova EV; Petrov SY; Germanova VN
    Vestn Oftalmol; 2020; 136(4):76-84. PubMed ID: 32779459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study.
    Higginbotham EJ; Olander KW; Kim EE; Grunden JW; Kwok KK; Tressler CS;
    Arch Ophthalmol; 2010 Feb; 128(2):165-72. PubMed ID: 20142538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
    Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA
    Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.